NCT00997997View on ClinicalTrials.gov

Avelox in Complicated Skin and Skin Structure Infections

CompletedOBSERVATIONAL
Enrollment

6,127

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Skin Diseases, Bacterial
Interventions
DRUG

Moxifloxacin (Avelox, BAY12-8039)

400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information

Trial Locations (12)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00997997 - Avelox in Complicated Skin and Skin Structure Infections | Biotech Hunter | Biotech Hunter